Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Enzalutamide and PDS01ADC in pprPC
NCT06096870Phase 2Recruiting
- Sponsor
- National Cancer Institute
- Start
- Apr 2024
- Primary completion
- Dec 2028
- Countries
- 1
01
Overview
A Phase 2 trial of NHS-IL-12 in recurrent prostate cancer (RPC), sponsored by National Cancer Institute. Started Apr 2024; status: recruiting.
02
Drugs
NHS-IL-12
03
Conditions
recurrent prostate cancer (RPC)
Beyond the preview
Go deeper on NCT06096870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06096870.